Vaping is NOT acceptable for patients being evaluated for bronchoscopic lung-volume reduction and should be discontinued.
Patients must stop vaping before undergoing bronchoscopic lung-volume reduction (BLVR) procedures due to documented risks of acute lung injury, respiratory complications, and the procedure's classification as a delayable elective intervention requiring optimal pulmonary status.
Rationale for Discontinuation
BLVR as a Delayable Procedure
Bronchoscopic lung volume reduction is explicitly categorized as a delayable (2-4 weeks) elective procedure 1. This classification provides a critical window to optimize the patient's pulmonary status by eliminating modifiable risk factors, with vaping being a significant one.
Direct Pulmonary Risks from Vaping
The evidence demonstrates multiple mechanisms by which vaping compromises lung health:
Acute lung injury (EVALI): Vaping causes acute respiratory disease that can be life-threatening, presenting with hypoxemic respiratory failure, ground-glass opacities, and consolidation on CT imaging 2. This directly contradicts the stable pulmonary status required for elective BLVR.
Chronic respiratory symptoms: Vaping is associated with persistent cough, dyspnea, and wheeze 3. These symptoms would confound post-procedural assessment and potentially worsen outcomes.
Spectrum of lung disease: Beyond EVALI, vaping causes pneumothorax, hypersensitivity pneumonitis, bronchiolitis obliterans, exogenous lipoid pneumonia, and diffuse alveolar hemorrhage 3, 4. Any of these conditions would be absolute or relative contraindications to BLVR.
Impaired lung function: Vaping enhances metabolic stress, impedes lung development, weakens immunity, and causes epithelial-mesenchymal transition, redox stress, mitochondrial toxicity, and DNA damage 4, 5.
Perioperative Complications
While one retrospective study found vaping associated with only minimal hypoxemia (4% change in SpO2/FiO2 ratio) without increased pulmonary complications 6, this study:
- Examined general noncardiothoracic surgeries, not high-risk pulmonary procedures
- Could not definitively exclude deleterious effects
- Explicitly stated anesthesiologists should consider potential perioperative complications
The authors themselves cautioned against interpreting their findings as evidence of safety 6.
BLVR-Specific Mortality Risk
The mortality risk from BLVR itself is substantial. In a recent cohort, 6% post-procedural mortality was documented, with 11% developing pneumonia and 3 patients developing fatal necrotizing pneumonia 7. Adding vaping-related lung injury risk to this baseline mortality is clinically unacceptable.
Clinical Algorithm for Management
Screen all BLVR candidates for vaping: Ask specifically about e-cigarette use within the past year, frequency, nicotine concentration, and substances vaped 5.
Mandate cessation: Require complete discontinuation of vaping for a minimum of 2-4 weeks before the procedure (aligning with the delayable classification) 1.
Provide cessation support: Offer evidence-based tobacco/nicotine cessation interventions, including behavioral counseling and pharmacotherapy 8. The same interventions proven for cigarette smoking cessation should be applied.
Reassess pulmonary status: After the cessation period, confirm absence of acute respiratory symptoms, stable pulmonary function tests, and no new radiographic abnormalities before proceeding.
Document compliance: Verify cessation through patient history and consider biochemical verification if concerns exist.
Common Pitfalls to Avoid
Assuming vaping is "safer" than smoking: While vaping may lack some tobacco combustion products, it generates harmful and potentially oncogenic byproducts 4. It is not safe.
Failing to ask about vaping: Many clinicians only ask about cigarette smoking. Explicitly inquire about e-cigarettes, vaping devices, and all electronic nicotine delivery systems 5.
Proceeding with BLVR in active vapers: The elective nature of BLVR and documented pulmonary risks of vaping make this combination unacceptable from a risk-benefit perspective.
Ignoring substance content: Ask what substances are being vaped (nicotine, THC, vitamin E acetate, etc.), as different compounds carry different risks 2.
Bottom Line
Vaping must be discontinued before bronchoscopic lung-volume reduction. The procedure's classification as delayable, combined with vaping's documented acute and chronic pulmonary toxicity, and BLVR's inherent mortality risk, makes continuing vaping while pursuing this elective intervention medically inappropriate. Prioritize patient safety by requiring cessation and optimizing pulmonary status before proceeding.